Needham Downgrades DICE Therapeutics to Hold
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Serge Belanger has downgraded DICE Therapeutics (NASDAQ:DICE) from Buy to Hold.
June 26, 2023 | 8:22 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
DICE Therapeutics (NASDAQ:DICE) has been downgraded from Buy to Hold by Needham analyst Serge Belanger.
The downgrade from Buy to Hold by Needham analyst Serge Belanger indicates a less optimistic outlook for DICE Therapeutics' stock performance in the short term. This could lead to a negative impact on the stock price as investors may adjust their positions based on the new rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100